Filing Details

Accession Number:
0001209191-21-021828
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-03-18 17:46:20
Reporting Period:
2021-03-16
Accepted Time:
2021-03-18 17:46:20
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1490978 Schrodinger Inc. SDGR Pharmaceutical Preparations (2834) 954284541
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1797782 Jorg Weiser C/O Schrodinger, Inc.,
120 West 45Th Street, 17Th Floor
New York NY 10036
Evp & Managing Director No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-03-16 18,095 $3.07 181,511 No 4 M Direct
Common Stock Disposition 2021-03-16 18,095 $82.00 163,416 No 4 S Direct
Common Stock Acquisiton 2021-03-16 6,527 $4.34 169,943 No 4 M Direct
Common Stock Disposition 2021-03-16 6,527 $82.00 163,416 No 4 S Direct
Common Stock Disposition 2021-03-16 37,060 $82.00 126,356 No 4 S Direct
Common Stock Disposition 2021-03-17 6,600 $78.07 119,756 No 4 S Direct
Common Stock Disposition 2021-03-17 1,500 $79.70 118,256 No 4 S Direct
Common Stock Disposition 2021-03-17 904 $80.85 117,352 No 4 S Direct
Common Stock Disposition 2021-03-17 300 $81.33 117,052 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2021-03-16 18,095 $0.00 18,095 $3.07
Common Stock Stock Option (right to buy) Disposition 2021-03-16 6,527 $0.00 6,527 $4.34
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2026-05-10 No 4 M Direct
9,614 2028-11-29 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 17,390 Indirect BY ANTERIO CONSULT AND RESEARCH GMBH
Footnotes
  1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2020.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.73 to $78.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4) of this Form 4.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.25 to $80.18, inclusive.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.32 to $81.31, inclusive.
  5. The shares are beneficially owned by Anterio Consult & Research GmbH ("Anterio"). Dr. Weiser is a shareholder and former managing director of Anterio and disclaims beneficial ownership of the shares held by Anterio, except to the extent of his pecuniary interest therein, if any.
  6. The option was granted on May 11, 2016 and is fully vested.
  7. This option was granted on November 29, 2018. The shares underlying the option vested with respect to 25% of the shares on December 31, 2019 and the remainder are scheduled to vest in equal monthly installments through December 31, 2022.